RTA 408 in the Treatment of Advanced Solid Tumors (NSCLC & Melanoma) - DISCOVER
Completed
AbbVie
Phase 1
2013-12-01
This proposed first-in-human study (408-C-1303) is designed to assess the safety, maximum
tolerated dose, pharmacodynamics, and pharmacokinetics of omaveloxolone (RTA 408) in patients
with advanced solid tumors that are refractory after standard of care therapy for the
disease. The results of this study will help provide clinical information for the design and
conduct of further clinical studies with RTA 408 in cancer patients.
RTA 408 in the Treatment of Advanced Solid Tumors (NSCLC & Melanoma) - DISCOVER
Completed
Reata Pharmaceuticals, Inc.
Phase 1
2013-12-01
This proposed first-in-human study (408-C-1303) is designed to assess the safety, maximum
tolerated dose, pharmacodynamics, and pharmacokinetics of omaveloxolone (RTA 408) in patients
with advanced solid tumors that are refractory after standard of care therapy for the
disease. The results of this study will help provide clinical information for the design and
conduct of further clinical studies with RTA 408 in cancer patients.
RTA 408 Ophthalmic Suspension for the Prevention of Corneal Endothelial Cell Loss Following Cataract Surgery - GUARD
Completed
AbbVie
Phase 2
2014-05-01
This study assesses the efficacy and safety of two concentrations of omaveloxolone (RTA 408)
ophthalmic suspension for the prevention of corneal endothelial cell loss following cataract
surgery.
RTA 408 Ophthalmic Suspension for the Prevention of Corneal Endothelial Cell Loss Following Cataract Surgery - GUARD
Completed
Reata Pharmaceuticals, Inc.
Phase 2
2014-05-01
This study assesses the efficacy and safety of two concentrations of omaveloxolone (RTA 408)
ophthalmic suspension for the prevention of corneal endothelial cell loss following cataract
surgery.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
